Author

Dalton Chapman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Synthetic Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Assay:protein sequence· 1 Assay:proteomics· 1

Frequent Co-Authors

Amir Shanehsazzadeh· 2 shared Breanna K. Luton· 2 shared Cailen M. McCloskey· 2 shared Chelsea Chung· 2 shared Christa Kohnert· 2 shared Douglas Ganini da Silva· 2 shared Gaelin Kopec-Belliveau· 2 shared George W. Kasun· 2 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSynthetic Biology

Amir Shanehsazzadeh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

Amir Shanehsazzadeh, Julian Alverio, George W. Kasun, Simon Levine, Ido Calman, Jibran Ahmad Khan, Chelsea Chung, Nicolas Diaz, Breanna K. Luton, Ysis Tarter, Cailen M. McCloskey, Katherine B. Bateman, Hayley Carter, Dalton Chapman, Rebecca Consbruck, , Sharrol T. Bachas

IgDesign designs antibody CDRs using deep learning and validates them in vitro, showing high success rates and improved affinities for multiple therapeutic antigens.

bioRxiv · Dec 8, 2023 · PreprintSynthetic Biology

Unlocking de novo antibody design with generative artificial intelligence

Amir Shanehsazzadeh, Matt McPartlon, George W. Kasun, Andrea K. Steiger, John M. Sutton, Edriss Yassine, Cailen M. McCloskey, Robel Gemechu Haile, Richard W. Shuai, Julian Alverio, Goran Rakočević, Simon Levine, Jovan Cejovic, Jahir M. Gutierrez, Alex Morehead, , Sharrol T. Bachas

Deep generative models combined with high-throughput screening design de novo anti-HER2 antibodies without further optimization, yielding nanomolar binders functionally comparable or superior to trastuzumab.

bioRxiv · Jan 8, 2023 · PreprintSynthetic Biology